research Alopecia Areata Profiling Shows TH1, TH2, and IL-23 Cytokine Activation Without Parallel TH17/TH22 Skewing
Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.
Search
for
Sort by
Research
30-60 / 1000+ results 
research Topical Janus Kinase Inhibitors: A Review of Applications in Dermatology
Topical JAK inhibitors may help treat some skin conditions but need more research.
research Experience with Oral Tofacitinib in Severe Alopecia Areata with Different Clinical Responses
Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
research The Evaluation of JAK Inhibitors on Effect and Safety in Alopecia Areata: A Systematic Review and Meta-Analysis of 2018 Patients
JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
research Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.
research Rapid Hair Regrowth in an Alopecia Universalis Patient With Deucravacitinib: A Case Report
A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.
research Baricitinib for the Treatment of Alopecia Areata
Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
research Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata
Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
research Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
research A Case of Vitiligo Combined With Systemic Lupus Erythematosus Treated With Tofacitinib
Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
research Tyrosine Kinase Inhibitors in Dermatology: A Systematic Review
Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.
research Benefit and Risk Profile of Tofacitinib for the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis
Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
research Treatment of Alopecia Areata and Its Numerous Possibilities: A Literature Review
Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.
research Treatment of Alopecia Areata: An Australian Expert Consensus Statement
Alopecia areata treatment varies, with no optimal method established yet.
research Unmet Medical Needs in Chronic, Non-Communicable Inflammatory Skin Diseases
There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.
research New Drugs Under Investigation for the Treatment of Alopecias
New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
research Emerging Drugs for Alopecia Areata: JAK Inhibitors
JAK inhibitors may soon be a safe and effective treatment for alopecia areata.
research Alopecia Areata: Overview and Treatment Options
Alopecia Areata is an autoimmune hair loss condition that needs more research for better treatments.
research Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib: A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata
A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
research Alopecia Areata: An Autoimmune Hair Loss Condition
Alopecia Areata is an unpredictable autoimmune hair loss condition with limited and variable treatment effectiveness.
research Treatment of Severe Alopecia Areata with Baricitinib
Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
research Tofacitinib Treatment in Patients With Active COVID-19 Infection
Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
research Recalcitrant Alopecia Areata Responsive to Leflunomide and Anthralin—Potentially Undiscovered JAK/STAT Inhibitors?
Leflunomide and anthralin may effectively treat severe alopecia areata.
research Myocardial NF-κB Activation Is Essential for Zebrafish Heart Regeneration
NF-κB is crucial for zebrafish heart repair, affecting heart cell growth and repair processes.
research Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
research Inflammatory Loops in the Epithelial-Immune Microenvironment of the Skin and Skin Appendages in Chronic Inflammatory Diseases
Chronic inflammatory skin diseases are caused by disrupted interactions between skin cells and immune cells.
research Alopecia Areata: A Review on Diagnosis, Immunological Etiopathogenesis, and Treatment Options
The document concludes that while there are various treatments for Alopecia Areata, there is no cure, and individualized treatment plans are essential due to varying effectiveness.
research A Randomized Placebo-Controlled Single-Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects with Moderate-to-Severe Alopecia Areata
Apremilast was not effective in treating moderate-to-severe alopecia areata.
research Topical SCD-153, A 4-Methyl Itaconate Prodrug, For The Treatment Of Alopecia Areata
SCD-153 shows promise as an effective topical treatment for alopecia areata.